非小细胞肺癌中RET融合基因的研究进展  

Research progress of RET fusion gene in non-small cell lung cancer

作　　者：方霆[1] 李代强[1] 

机构地区：[1]中南大学湘雅二医院病理科,长沙410011

出　　处：《临床与病理杂志》2015年第2期284-288,共5页Journal of Clinical and Pathological Research

摘　　要：存在于1%-2%的非小细胞肺癌患者中的RET融合基因具有鲜明的临床病理学特征,且RET抑制剂对其治疗有效,提示RET融合基因已成为该类患者个体化分子靶向治疗的新靶点。本文将对RET融合基因的特点及其在非小细胞肺癌（non-small cell lung cancer,NSCLC）患者中的表达和治疗的研究进展进行阐述。RET fusion gene with an identifiable clinicopathological characteristics, is present in 1% to 2% of non-small cell lung cancer patients, and its treatment is effective by RET inhibitor, suggesting that RET fusion gene is a new target for individualized treatment to the patients of NSCLC. Th is article reviews the characteristics of RET fusion gene and expression patt erns in patients, and treatment of NSCLC.

关 键 词：RET融合基因 非小细胞肺癌 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]